{
    "relation": [
        [
            "",
            "Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV)",
            "Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV"
        ],
        [
            "Description",
            "1 tablet (600mg/300mg) ABC/3TC + 800mg/200mg LPV/RTV combination therapy once daily",
            "1 tablet (300mg/200mg) TDF/FTC + 800mg/200mg LPV/RTV combination therapy once daily"
        ]
    ],
    "pageTitle": "Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00244712?sect=Xk0156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988930.94/warc/CC-MAIN-20150728002308-00239-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 872810095,
    "recordOffset": 872791843,
    "tableOrientation": "VERTICAL",
    "textBeforeTable": "Reporting Groups After screening, participants who had never received treatment for HIV-1 infection and had a viral load greater than or equal to 1,000 copies per milliliter of blood and any amount of CD4+ T-cells were equally randomized to 1 of 2 treatment groups. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Participants were recruited at 76 study sites in the US and 2 study sites in Puerto Rico between 26 July 2005 and 16 June 2006. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: emtricitabine/tenofovir Drug: abacavir/lamivudine Interventions: HIV Infection Condition:",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) \u00a0 \u00a0 Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV \u00a0 STARTED \u00a0 \u00a0 343 \u00a0 \u00a0 345 \u00a0 COMPLETED \u00a0 \u00a0 234 \u00a0 \u00a0 221 \u00a0 NOT COMPLETED \u00a0 \u00a0 109 \u00a0 \u00a0 124 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 20 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 21 \u00a0 Protocol-Defined Virologic Failure \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 8 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 6 \u00a0 Lack of Compliance \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 10 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}